MA43345A - Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation - Google Patents

Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation

Info

Publication number
MA43345A
MA43345A MA43345A MA43345A MA43345A MA 43345 A MA43345 A MA 43345A MA 43345 A MA43345 A MA 43345A MA 43345 A MA43345 A MA 43345A MA 43345 A MA43345 A MA 43345A
Authority
MA
Morocco
Prior art keywords
methods
drug conjugates
antibody
pyrrolobenzodiazepine
drug
Prior art date
Application number
MA43345A
Other languages
English (en)
Inventor
Peter DRAGOVICH
Thomas Pillow
Jack Sadowsky
Mark X Sliwkowski
Binqing Wei
Original Assignee
Hoffmann La Roche
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication date
Publication of MA43345A publication Critical patent/MA43345A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Abstract

L'invention concerne des conjugués anticorps-médicaments comprenant un anticorps conjugué à un fragment de médicament de pyrrolobenzodiazépine par l'intermédiaire d'un lieur disulfure, des intermédiaires de médicaments-lieurs de pyrrolobenzodiazépine, et des procédés d'utilisation des conjugués anticorps-médicaments.
MA43345A 2015-10-02 Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation MA43345A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562236429P 2015-10-02 2015-10-02

Publications (1)

Publication Number Publication Date
MA43345A true MA43345A (fr) 2018-08-08

Family

ID=57145040

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43345A MA43345A (fr) 2015-10-02 Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation

Country Status (25)

Country Link
US (3) US10058613B2 (fr)
EP (1) EP3355935B1 (fr)
JP (3) JP6663984B2 (fr)
KR (1) KR102111338B1 (fr)
CN (1) CN108391422B (fr)
AR (1) AR106235A1 (fr)
AU (1) AU2016331931C1 (fr)
BR (1) BR112018006016A2 (fr)
CA (1) CA2996902C (fr)
CL (1) CL2018000813A1 (fr)
CO (1) CO2018004152A2 (fr)
CR (1) CR20180243A (fr)
HK (1) HK1259127A1 (fr)
IL (1) IL258046A (fr)
MA (1) MA43345A (fr)
MX (1) MX2018003628A (fr)
NZ (1) NZ741261A (fr)
PE (1) PE20181067A1 (fr)
PH (1) PH12018500693A1 (fr)
RU (1) RU2736725C1 (fr)
SG (1) SG10201912680RA (fr)
TW (1) TW201718027A (fr)
UA (1) UA123104C2 (fr)
WO (1) WO2017059289A1 (fr)
ZA (1) ZA201801957B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101839163B1 (ko) 2010-06-08 2018-03-15 제넨테크, 인크. 시스테인 조작된 항체 및 접합체
MY186334A (en) 2014-09-12 2021-07-12 Genentech Inc Anti-her2 antibodies and immunoconjugates
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) * 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
EP3496763A1 (fr) 2016-08-11 2019-06-19 Genentech, Inc. Promédicaments de pyrrolobenzodiazépine et conjugués d'anticorps de ceux-ci
BR112020004126A2 (pt) 2017-09-29 2020-09-08 Daiichi Sankyo Company, Limited conjugado anticorpo-derivado de pirrolbenzodiazepina
US20200384002A1 (en) * 2017-12-06 2020-12-10 Yale University Prodrugs Activated by Reduction in the Cytosol
GB201803342D0 (en) * 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP2022511337A (ja) 2018-09-19 2022-01-31 インサーム （インスティテュート ナショナル デ ラ サンテ エ デ ラ ルシェルシェ メディカル） 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物
CN113227119A (zh) 2018-12-10 2021-08-06 基因泰克公司 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
EP3914241A4 (fr) * 2019-01-25 2023-01-18 Yale University Médicaments anticancéreux et leurs procédés de production et d'utilisation
AU2020219736A1 (en) * 2019-02-04 2021-09-30 Xenetic Biosciences, Inc. Methods of using glycopolysialylated therapeutic proteins
CA3191804A1 (fr) * 2019-03-25 2020-10-01 Daiichi Sankyo Company, Limited Conjugue anticorps anti-her2/derive de pyrrolobenzodiazepine
KR20210143839A (ko) * 2019-03-27 2021-11-29 다이이찌 산쿄 가부시키가이샤 항체-피롤로벤조디아제핀 유도체 콘주게이트와 parp 저해제의 조합
US20220363776A1 (en) 2019-10-04 2022-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
WO2021113740A1 (fr) * 2019-12-04 2021-06-10 The Research Foundation For The State University Of New York Compositions et procédés visant à réduire la toxicité hors cible de conjugués anticorps-médicament
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
EP4189071A1 (fr) 2020-08-03 2023-06-07 Institut National de la Santé et de la Recherche Médicale (INSERM) Population de lymphocytes treg fonctionnellement engagés dans l'exercice d'une activité régulatrice et leur utilisation en thérapie adoptive
CN112125924B (zh) * 2020-09-15 2021-09-24 吉林大学 一种螺旋寡聚物、仿生离子通道、制备方法、应用
KR20230135107A (ko) 2021-01-22 2023-09-22 바이엘 악티엔게젤샤프트 Lrrc15 항체 및 그의 접합체
WO2023215293A1 (fr) 2022-05-02 2023-11-09 Athanor Biosciences, Inc. Bio-nanoparticules anticancéreuses (ce-bnp)

Family Cites Families (389)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US798959A (en) 1904-12-19 1905-09-05 George W Goss Corn-husker.
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4427588A (en) 1982-11-08 1984-01-24 Bristol-Myers Company Process for conversion of oxotomaymycin to tomaymycin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
FI891226A (fi) 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
WO1990008187A1 (fr) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Proteine cd2 soluble a deux domaines
CA2046909A1 (fr) 1989-03-21 1990-09-22 Mark D. Howell Vaccination et methodes d'immunisation contre les maladies resultant de reactions pathogenes provoquees par des populations de lymphocytes t
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2112838T5 (es) 1989-07-19 2004-09-01 Connetics Corporation Peptidos receptores de celulas t como agentes terapeuticos para enfermedades autoinmunitarias y malignas.
CA2023779A1 (fr) 1989-08-23 1991-02-24 Margaret D. Moore Composes et methodes pour la detection et le traitement des infections a virus epstein-barr et des troubles de l'immunite
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
JPH053790A (ja) 1990-04-19 1993-01-14 Fujisawa Pharmaceut Co Ltd デヒドロペプチダーゼ−ｉ
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992007574A1 (fr) 1990-10-25 1992-05-14 Tanox Biosystems, Inc. Glycoproteines associees a des immunoglobulines a liaison membranaire et utilisees comme cibles anticorpales sur des cellules b
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5440021A (en) 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
WO1992017497A1 (fr) 1991-03-29 1992-10-15 Genentech, Inc. Receptor humain pf4a et leur utilisation
US5543503A (en) 1991-03-29 1996-08-06 Genentech Inc. Antibodies to human IL-8 type A receptor
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
JP3050424B2 (ja) 1991-07-12 2000-06-12 塩野義製薬株式会社 ヒトエンドセリンリセプター
US5264557A (en) 1991-08-23 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Polypeptide of a human cripto-related gene, CR-3
WO1993006217A1 (fr) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION DANS L'E. COLI DE FRAGMENTS D'ANTICORPS POSSEDANT AU MOINS UNE CYSTEINE PRESENTE SOUS FORME D'UN THIOL LIBRE, ET LEUR UTILISATION DANS LA PRODUCTION D'ANTICORPS BIFONCTIONNELS F(ab')¿2?
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
US6153408A (en) 1991-11-15 2000-11-28 Institut Pasteur And Institut National De La Sante Et De La Recherche Medicale Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
US5976551A (en) 1991-11-15 1999-11-02 Institut Pasteur And Institut Nationale De La Sante Et De La Recherche Medicale Altered major histocompatibility complex (MHC) determinant and method of using the determinant
EP1997894B1 (fr) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Protéine de liaison biosynthétique pour un marqueur du cancer
IL107366A (en) 1992-10-23 2003-03-12 Chugai Pharmaceutical Co Ltd Genes coding for megakaryocyte potentiator
US5644033A (en) 1992-12-22 1997-07-01 Health Research, Inc. Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5869445A (en) 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
CA2163345A1 (fr) 1993-06-16 1994-12-22 Susan Adrienne Morgan Anticorps
US5773223A (en) 1993-09-02 1998-06-30 Chiron Corporation Endothelin B1, (ETB1) receptor polypeptide and its encoding nucleic acid methods, and uses thereof
US5750370A (en) 1995-06-06 1998-05-12 Human Genome Sciences, Inc. Nucleic acid encoding human endothlein-bombesin receptor and method of producing the receptor
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US20020193567A1 (en) 1995-08-11 2002-12-19 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
JP3646191B2 (ja) 1996-03-19 2005-05-11 大塚製薬株式会社 ヒト遺伝子
SK157498A3 (en) 1996-05-17 1999-10-08 Schering Corp Isolated and recombinant nucleic acid, bas-1 protein or peptide thereof, and agent, antibody, expression vector, host cell and method of their use
AU4982097A (en) * 1996-10-18 1998-05-15 Board Of Regents, The University Of Texas System Anti-erbb2 antibodies
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6261791B1 (en) 1997-03-10 2001-07-17 The Regents Of The University Of California Method for diagnosing cancer using specific PSCA antibodies
JP4404381B2 (ja) 1997-03-10 2010-01-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｐｓｃａ：前立腺幹細胞抗原
US6541212B2 (en) 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
US6319688B1 (en) 1997-04-28 2001-11-20 Smithkline Beecham Corporation Polynucleotide encoding human sodium dependent phosphate transporter (IPT-1)
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
US6890749B2 (en) 1997-05-15 2005-05-10 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
WO1998051824A1 (fr) 1997-05-15 1998-11-19 Abbott Laboratories Reactifs et procedes utiles au depistage de maladies du tractus urinaire
WO1998058964A1 (fr) 1997-06-24 1998-12-30 Genentech, Inc. Procedes et compositions concernant des glycoproteines galactosylees
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
US20030060612A1 (en) 1997-10-28 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO1999022764A1 (fr) 1997-10-31 1999-05-14 Genentech, Inc. Compositions renfermant des glycoformes de glycoproteine et methodes afferentes
US20020034749A1 (en) 1997-11-18 2002-03-21 Billing-Medel Patricia A. Reagents and methods useful for detecting diseases of the breast
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
US6110695A (en) 1997-12-02 2000-08-29 The Regents Of The University Of California Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
WO1999046284A2 (fr) 1998-03-13 1999-09-16 The Burnham Institute Molecules se logeant dans divers organes ou tissus
EP1064027B1 (fr) 1998-03-27 2008-06-18 Genentech, Inc. Synergie des anticorps anti-her-2 et des ligands pour l'apo-2
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP2002510481A (ja) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド 抗体変異体及びその断片
EP2261229A3 (fr) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Modification par glycosylation d'anticorps aux fins d'amélioration de la cytotoxicité cellulaire dépendant des anticorps
AU4078599A (en) 1998-05-13 1999-11-29 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
US20020187472A1 (en) 2001-03-09 2002-12-12 Preeti Lal Steap-related protein
US20030064397A1 (en) 1998-05-22 2003-04-03 Incyte Genomics, Inc. Transmembrane protein differentially expressed in prostate and lung tumors
EP1413582B1 (fr) 1998-08-27 2006-03-15 Spirogen Limited Pyrrolobenzodiazépines dimériques
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
WO2000012130A1 (fr) 1998-08-27 2000-03-09 Smithkline Beecham Corporation Agonistes et antagonistes de rp105
JP4689781B2 (ja) 1998-09-03 2011-05-25 独立行政法人科学技術振興機構 アミノ酸輸送蛋白及びその遺伝子
AU5963699A (en) 1998-10-02 2000-04-26 Mcmaster University Spliced form of (erb)b-2/neu oncogene
WO2001057188A2 (fr) 2000-02-03 2001-08-09 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides
US6468546B1 (en) 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6962980B2 (en) 1999-09-24 2005-11-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20030091580A1 (en) 2001-06-18 2003-05-15 Mitcham Jennifer L. Compositions and methods for the therapy and diagnosis of ovarian cancer
US6858710B2 (en) 1998-12-17 2005-02-22 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20030190669A1 (en) 1998-12-30 2003-10-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2002536966A (ja) 1998-12-30 2002-11-05 ベス・イスラエル・ディーコニス・メディカル・センター・インコーポレーテッド カルシウムチャネルファミリーの特徴付け
JP2003512019A (ja) 1999-01-15 2003-04-02 ジェネンテック・インコーポレーテッド 変化したエフェクター機能を有するポリペプチド変異体
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1147190B1 (fr) 1999-01-29 2010-07-14 Corixa Corporation Proteines de fusion her-2/neu
GB9905124D0 (en) 1999-03-05 1999-04-28 Smithkline Beecham Biolog Novel compounds
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
ES2420835T3 (es) 1999-04-09 2013-08-27 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de las moléculas inmunofuncionales
US7312303B2 (en) 1999-05-11 2007-12-25 Genentech, Inc. Anti-PRO4980 antibodies
AU4952600A (en) 1999-06-03 2000-12-28 Takeda Chemical Industries Ltd. Screening method with the use of cd100
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
BRPI0017590B8 (pt) 1999-06-25 2021-05-25 Genentech Inc conjugado de maitansinoide - anticorpo anti-erbb, e formulação farmacêutica
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7589172B2 (en) 1999-07-20 2009-09-15 Genentech, Inc. PRO256 polypeptides
US7297770B2 (en) 1999-08-10 2007-11-20 Genentech, Inc. PRO6496 polypeptides
US7294696B2 (en) 1999-08-17 2007-11-13 Genentech Inc. PRO7168 polypeptides
AU7573000A (en) 1999-09-01 2001-03-26 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030232056A1 (en) 1999-09-10 2003-12-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20030206918A1 (en) 1999-09-10 2003-11-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20030129192A1 (en) 1999-09-10 2003-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
MXPA02003456A (es) 1999-10-04 2002-10-23 Medicago Inc Metodo para regular la transcripcion de genes foraneos.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6750054B2 (en) 2000-05-18 2004-06-15 Lexicon Genetics Incorporated Human semaphorin homologs and polynucleotides encoding the same
JP4668498B2 (ja) 1999-10-19 2011-04-13 協和発酵キリン株式会社 ポリペプチドの製造方法
CA2387108A1 (fr) 1999-10-29 2001-06-07 Genentech, Inc. Compositions a base d'anticorps diriges contre l'antigene de cellules souches de la prostate (psca) et procedes d'utilisation associes
ES2586850T3 (es) 1999-11-29 2016-10-19 The Trustees Of Columbia University In The City Of New York Aislamiento de cinco genes novedosos que codifican nuevos melanomas de tipo receptor de Fc implicados en la patogénesis del linfoma/melanoma
EP1248800A2 (fr) 1999-11-30 2002-10-16 Corixa Corporation Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
AU2087401A (en) 1999-12-10 2001-06-18 Epimmune, Inc. Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
WO2001044463A1 (fr) 1999-12-15 2001-06-21 Genentech, Inc. Balayage aveugle, procede combinatoire permettant la representation d'epitopes de proteines fonctionnelles
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
DK1246846T3 (da) 1999-12-23 2008-12-08 Zymogenetics Inc Oplöselig interleukin-20-receptor
NZ502058A (en) 1999-12-23 2003-11-28 Ovita Ltd Isolated mutated nucleic acid molecule for regulation of ovulation rate
JP2003535037A (ja) 1999-12-23 2003-11-25 ザイモジェネティクス，インコーポレイティド 炎症を治療する方法
US7294695B2 (en) 2000-01-20 2007-11-13 Genentech, Inc. PRO10268 polypeptides
EP1252294A2 (fr) 2000-01-21 2002-10-30 Corixa Corporation Composes et procedes de prevention et de traitement de tumeurs malignes associes a her-2/neu
US20030224379A1 (en) 2000-01-21 2003-12-04 Tang Y. Tom Novel nucleic acids and polypeptides
US20020142377A1 (en) 2000-02-22 2002-10-03 Glucksmann Maria Alexandra 18607, a novel human calcium channel
US20030219806A1 (en) 2000-02-22 2003-11-27 Millennium Pharmaceuticals, Inc. Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor
US20040005561A1 (en) 2000-03-01 2004-01-08 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
AU2001245280A1 (en) 2000-03-07 2001-09-17 Hyseq, Inc. Novel nucleic acids and polypeptides
AU4941101A (en) 2000-03-24 2001-10-08 Fahri Saatcioglu Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides,and diagnostic and therapeutic methods
WO2004043361A2 (fr) 2002-11-08 2004-05-27 Genentech, Inc. Compositions et procedes de traitement des maladies liees aux cellules k naturelles
JP2003530325A (ja) 2000-03-31 2003-10-14 イーペーエフ ファルマシューティカルス ゲゼルシャフト ミット ベシュレンクテル ハフツング 好ましくは特異的ケモカインレセプター分析、及びケモカインレセプター／リガンド相互作用の助けによる、腫瘍及び炎症細胞の細胞表面プロテオームの調査、並びに腫瘍疾患及び炎症性疾患の治療のための診断薬及び薬剤
WO2001075177A2 (fr) 2000-04-03 2001-10-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Marqueurs tumoraux pour le cancer des ovaires
JP2003532057A (ja) 2000-04-07 2003-10-28 アリーナ・フアーマシユーチカルズ・インコーポレーテツド 非内因性の、構成的に活性化される既知ｇタンパク質−共役受容体
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
US20030119115A1 (en) 2000-05-17 2003-06-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001090304A2 (fr) 2000-05-19 2001-11-29 Human Genome Sciences, Inc. Acides nucleiques, proteines et anticorps
PL400669A1 (pl) 2000-05-19 2012-11-05 Genentech, Inc. Genowa próba wykrywania odpowiedzi na antagoniste ErbB dla poprawienia prawdopodobienstwa i skutecznosci leczenia raka
WO2001094641A2 (fr) 2000-06-09 2001-12-13 Idec Pharmaceuticals Corporation Nouvelles cibles geniques et ligands se fixant a celles-ci pour le traitement et le diagnostic de carcinomes ovariens
EP1297130A2 (fr) 2000-06-16 2003-04-02 Incyte Genomics, Inc. Recepteur couple a la proteine g
AU2001273151A1 (en) 2000-06-30 2002-01-14 Incyte Genomics, Inc. Human extracellular matrix and cell adhesion polypeptides
CA2413262A1 (fr) 2000-06-30 2002-01-10 Amgen, Inc. Molecules de type b7 et utilisation de ces molecules
EP1301524A1 (fr) 2000-06-30 2003-04-16 Human Genome Sciences, Inc. Polynucl otides du type b7, polypeptides et anticorps en rapport
AU2002214531A1 (en) 2000-07-03 2002-01-30 Curagen Corporation Proteins and nucleic acids encoding same
US20040044179A1 (en) 2000-07-25 2004-03-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001283507A1 (en) 2000-07-27 2002-02-13 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
ATE396266T1 (de) 2000-07-28 2008-06-15 Ulrich Wissenbach Trp8 krebsmarker
US7229623B1 (en) 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
EP1366153A2 (fr) 2000-08-14 2003-12-03 Corixa Corporation Compositions et methodes de traitement et de diagnostic de cancers associes a her-2/neu
WO2002013847A2 (fr) 2000-08-14 2002-02-21 Corixa Corporation Methodes diagnostiques et therapeutiques des tumeurs malignes d'origine hematologiques et virales
US6984494B2 (en) 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
EP1311674A2 (fr) 2000-08-24 2003-05-21 Genentech, Inc. Compositions et procedes de diagnostic et traitement de tumeurs
GB0020953D0 (en) 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
EP1346040A2 (fr) 2000-09-11 2003-09-24 Nuvelo, Inc. Noveaux acides nucleiques et polypeptides
DE60121808T2 (de) 2000-09-15 2007-03-29 Zymogenetics, Inc., Seattle Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
US6613567B1 (en) 2000-09-15 2003-09-02 Isis Pharmaceuticals, Inc. Antisense inhibition of Her-2 expression
US20030119121A1 (en) 2000-09-15 2003-06-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
JP2004524810A (ja) 2000-09-18 2004-08-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｃｒｉｐｔｏ変異体およびその使用
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
CA2953239A1 (fr) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Cellules produisant des compositions d'anticorps
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2425569A1 (fr) 2000-10-13 2002-04-18 Eos Biotechnology, Inc. Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1407017T3 (en) 2000-11-07 2009-09-21 Zymogenetics Inc Human receptor for tumor nekrose faktor
US20020150573A1 (en) 2000-11-10 2002-10-17 The Rockefeller University Anti-Igalpha-Igbeta antibody for lymphoma therapy
CN101940189A (zh) 2000-11-30 2011-01-12 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
WO2002061087A2 (fr) 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques
US20020159986A1 (en) 2001-01-12 2002-10-31 John Langenfeld Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
US20030119126A1 (en) 2001-01-16 2003-06-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030119125A1 (en) 2001-01-16 2003-06-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JP2005503760A (ja) 2001-01-24 2005-02-10 プロテイン デザイン ラブス， インコーポレイテッド 乳癌の診断方法、組成物および乳癌のモジュレーターのスクリーニング方法
US20030073144A1 (en) 2001-01-30 2003-04-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
US20040170994A1 (en) 2001-02-12 2004-09-02 Callen David Frederick DNA sequences for human tumour suppressor genes
WO2002071928A2 (fr) 2001-03-14 2002-09-19 Millennium Pharmaceuticals, Inc. Molecules d'acide nucleique et proteines destinees a l'identification, l'evaluation, la prevention et la therapie du cancer des ovaires
WO2002078524A2 (fr) 2001-03-28 2002-10-10 Zycos Inc. Determination de profils translationnels
WO2003008537A2 (fr) 2001-04-06 2003-01-30 Mannkind Corporation Sequences d'epitope
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
WO2002083866A2 (fr) 2001-04-17 2002-10-24 The Board Of Trustees Of The University Of Arkansas Sequences repetees du gene ca125 et leurs utilisations dans des interventions diagnostiques et therapeutiques
WO2002086443A2 (fr) 2001-04-18 2002-10-31 Protein Design Labs, Inc Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon
SI1390389T1 (sl) 2001-04-26 2009-06-30 Biogen Idec Inc Protitelesa, ki blokirajo cripto in uporabe le-teh
AU2002334799B2 (en) 2001-04-26 2009-05-07 Biogen Ma Inc. Cripto-specific antibodies
EP1515982A4 (fr) 2001-05-09 2005-10-26 Corixa Corp Methodes et compositions pour la therapie et le diagnostic du cancer de la prostate
WO2002092836A2 (fr) 2001-05-11 2002-11-21 Sloan-Kettering Institute For Cancer Research Sequence nucleotidique codant un antigene ovarien ca125 et ses utilisations
KR20040030628A (ko) 2001-05-24 2004-04-09 지모제넥틱스, 인코포레이티드 Ｔａｃｉ-면역글로불린 융합 단백질
US7157558B2 (en) 2001-06-01 2007-01-02 Genentech, Inc. Polypeptide encoded by a polynucleotide overexpresses in tumors
WO2002098358A2 (fr) 2001-06-04 2002-12-12 Eos Biotechnology, Inc. Procedes de diagnostic et de traitement du cancer prostatique androgene-dependant, cancer prostatique subissant un retrait d'androgenes et cancer prostatique androgene-independant
JP2005518185A (ja) 2001-06-04 2005-06-23 キュラジェン コーポレイション 新規タンパク質およびそれをコード化する核酸
AU2002320264B2 (en) 2001-06-05 2008-05-01 Exelixis, Inc. GFATs as modifiers of the p53 pathway and methods of use
AU2002310256A1 (en) 2001-06-05 2002-12-16 Exelixis Inc. Ppp2cs as modifiers of the p53 pathway and methods of use
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
WO2002101075A2 (fr) 2001-06-13 2002-12-19 Millennium Pharmaceuticals, Inc. Identification, evaluation, prevention et traitement du cancer du col de l'uterus : nouveaux genes, nouvelles compositions, nouvelles trousses et nouvelles methodes
US7189507B2 (en) 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
EP1517998A2 (fr) 2001-06-18 2005-03-30 EOS Biotechnology, Inc. Procedes de diagnostic du cancer ovarien, compositions et procedes de criblage de modulateurs du cancer ovarien
US7705120B2 (en) 2001-06-21 2010-04-27 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003002717A2 (fr) 2001-06-28 2003-01-09 Schering Corporation Activite biologique de ak155
WO2003004529A2 (fr) 2001-07-02 2003-01-16 Licentia Ltd. Materiaux de recepteur ephrine-tie et leurs procedes
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
WO2003003984A2 (fr) 2001-07-05 2003-01-16 Curagen Corporation Nouvelles proteines et nouveaux acides nucleiques codant ces proteines
WO2003055439A2 (fr) 2001-07-18 2003-07-10 The Regents Of The University Of California Antigene cible her2/neu et son utilisation pour stimuler une reponse immunitaire
AU2002337657A1 (en) 2001-07-25 2003-02-17 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
EP1423510A4 (fr) 2001-08-03 2005-06-01 Glycart Biotechnology Ag Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
EA200601861A1 (ru) 2001-08-03 2007-02-27 Дженентек, Инк. ПОЛИПЕПТИДЫ TACIs И BR3 И ИХ ПРИМЕНЕНИЕ
US20070015145A1 (en) 2001-08-14 2007-01-18 Clifford Woolf Nucleic acid and amino acid sequences involved in pain
US20030092013A1 (en) 2001-08-16 2003-05-15 Vitivity, Inc. Diagnosis and treatment of vascular disease
AU2002313559A1 (en) 2001-08-23 2003-03-10 Oxford Biomedica (Uk) Limited Genes
AU2002357643A1 (en) 2001-08-29 2003-04-14 Vanderbilt University The human mob-5 (il-24) receptors and uses thereof
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
AU2002336446B2 (en) 2001-09-06 2008-03-06 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
JP2005518782A (ja) 2001-09-17 2005-06-30 プロテイン デザイン ラブス， インコーポレイテッド ガンの診断方法、ガンのモジュレータのスクリーニング組成物及び方法
IL160933A0 (en) 2001-09-18 2004-08-31 Proteologics Inc Methods and compositions for treating ?cap associated diseases
EP1487877B1 (fr) 2001-09-18 2010-10-27 Genentech, Inc. Compositions et procedes pour le diagnostic de tumeurs
CA2460621A1 (fr) 2001-09-19 2003-03-27 Nuvelo, Inc. Nouveaux acides nucleiques et polypeptides
US20030077644A1 (en) 2001-09-28 2003-04-24 Bing Yang Diagnosis and treatment of diseases caused by mutations in CD72
WO2003029277A2 (fr) 2001-10-03 2003-04-10 Rigel Pharmaceuticals, Inc. Modulateurs de l'activation et de la migration des lymphocytes
US20040249144A1 (en) 2001-10-03 2004-12-09 Zairen Sun Regulated breast cancer genes
US20030228319A1 (en) 2002-04-16 2003-12-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2002351505B2 (en) 2001-10-19 2008-04-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
US7825089B2 (en) 2001-10-24 2010-11-02 National Jewish Health Three-dimensional structures of TALL-1 and its cognate receptors and modified proteins and methods related thereto
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
MXPA04003697A (es) 2001-10-31 2005-04-08 Alcon Inc Proteinas morfogenicas de hueso (bmp), receptores de bmp y proteinas de enlace de bmp y su uso en el diagnostico y tratamiento de glaucoma.
WO2003042661A2 (fr) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer
US20030232350A1 (en) 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2003045422A1 (fr) 2001-11-29 2003-06-05 Genset S.A. Agonistes et antagonistes de la prolixine pour le traitement des troubles metaboliques
AU2002349784A1 (en) 2001-12-03 2003-06-17 Asahi Kasei Pharma Corporation Nf-kappab activating genes
WO2003054152A2 (fr) 2001-12-10 2003-07-03 Nuvelo, Inc. Nouveaux acides nucleiques et polypeptides
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20030134790A1 (en) 2002-01-11 2003-07-17 University Of Medicine And Dentistry Of New Jersey Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer
US7452675B2 (en) 2002-01-25 2008-11-18 The Queen's Medical Center Methods of screening for TRPM4b modulators
EP1485130A4 (fr) 2002-02-21 2006-11-22 Univ Duke Reactifs et methodes therapeutiques de maladies auto-immunes
CA2476518A1 (fr) 2002-02-22 2003-09-04 Genentech, Inc. Compositions et methodes de traitement de maladies relatives au systeme immunitaire
AU2003224638A1 (en) 2002-03-01 2003-09-16 Exelixis, Inc. PDPK1s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2003097803A2 (fr) 2002-05-15 2003-11-27 Avalon Pharmaceuticals Gene lie au cancer utilise comme cible pour la chimiotherapie
US6660856B2 (en) 2002-03-08 2003-12-09 Kaohsiung Medical University Synthesis of pyrrolo[2,1-c][1,4]benzodiazepine analogues
EP2258712A3 (fr) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions et procédés permettant d'initier ou d'ameliorer les réponses des cellules T limitées par le complexe majeur d 'histocompatibilité de classe I ou II et un anticorps au moyen de motifs d'ARN non codants immunomodulateurs
WO2004000997A2 (fr) 2002-03-19 2003-12-31 Curagen Corporation Polypeptides therapeutiques, acides nucleiques les codant et principes d'utilisation
JP2005534286A (ja) 2002-03-21 2005-11-17 サネシス ファーマシューティカルズ， インコーポレイテッド キナーゼインヒビターの同定
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
EP1490085A2 (fr) 2002-03-25 2004-12-29 Uab Research Foundation Homologues des recepteurs de fc, reactifs associes et leurs utilisations
WO2003083074A2 (fr) 2002-03-28 2003-10-09 Idec Pharmaceuticals Corporation Nouvelles cibles geniques et ligands se liant a celles-ci pour le traitement et le diagnostic de carcinomes du colon
US20030194704A1 (en) 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
BR0308953A (pt) 2002-04-05 2006-03-14 Agensys Inc composições, proteìna, polinucleotìdeo, método de geração de uma resposta imune, método de detecção, composição farmacêutica, anticorpo ou seu fragmento, animal transgênico, hibridoma, método de fornecimento de um agente citotóxico ou agente de diagnóstico e método de inibição do crescimento de células cancerosas
WO2003085119A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia
CA2481920A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition anticorps
AU2003236019A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
CA2481837A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede de production de composition anticorps
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
WO2003087768A2 (fr) 2002-04-12 2003-10-23 Mitokor Cibles pour une intervention therapeutique identifiee dans le proteome mitochondrial
US20030224467A1 (en) 2002-04-17 2003-12-04 Osborne C. Kent AIB1 as a prognostic marker and predictor of resistance to endocrine therapy
AU2003228869A1 (en) 2002-05-03 2003-11-17 Incyte Corporation Transporters and ion channels
AU2003232453A1 (en) 2002-05-30 2003-12-19 David K. Bol Human solute carrier family 7 member 11 (hslc7a11)
AU2003239966B9 (en) 2002-06-03 2010-08-26 Genentech, Inc. Synthetic antibody phage libraries
EP1575492A4 (fr) 2002-06-04 2007-05-09 Avalon Pharmaceuticals Gene lie au cancer comme cible de chimiotherapie
AU2003240495A1 (en) 2002-06-04 2003-12-19 Incyte Corporation Diagnostics markers for lung cancer
AU2003242633A1 (en) 2002-06-06 2003-12-22 Molecular Engines Laboratories Dudulin genes, non-human animal model: uses in human hematological disease
CA2488404C (fr) 2002-06-06 2012-11-27 Oncotherapy Science, Inc. Genes et polypeptides en rapport avec les cancers du colon chez l'homme
AU2003249691A1 (en) 2002-06-07 2003-12-22 Avalon Pharmaceuticals, Inc Cancer-linked gene as target for chemotherapy
AU2003245441A1 (en) 2002-06-12 2003-12-31 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
CA2487809A1 (fr) 2002-06-18 2003-12-24 Archemix Corp. Molecules toxine-aptamere et procedes d'utilisation correspondants
US20040249130A1 (en) 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
AU2003245615A1 (en) 2002-06-20 2004-01-06 The Regents Of The University Of California Compositions and methods for modulating lymphocyte activity
EP1534331B1 (fr) 2002-06-21 2014-10-29 Johns Hopkins University School of Medicine Marqueurs de l'endothelium tumoral associe a une membrane
AU2003281515A1 (en) 2002-07-19 2004-02-09 Cellzome Ag Protein complexes of cellular networks underlying the development of cancer and other diseases
BR0313033A (pt) 2002-07-25 2007-07-10 Genentech Inc anticorpos, anticorpos monoclonais, linhagens de células de hibridoma, anticorpos receptores de anti-taci isolados, anticorpos anti -taci, métodos de modulação da atividade biológica
AR040956A1 (es) 2002-07-31 2005-04-27 Schering Ag Nuevos conjugados de efectores, procedimientos para su preparacion y su uso farmaceutico
AU2003251471A1 (en) 2002-08-06 2004-02-25 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 5(cxcr5)
JP2004121218A (ja) 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
AU2003259163B2 (en) * 2002-08-16 2008-07-03 Immunogen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
CA2495389A1 (fr) 2002-08-19 2004-02-26 Genentech, Inc. Compositions et methodes de diagnostic et de traitement des tumeurs
JP2006515742A (ja) 2002-08-27 2006-06-08 ブリストル−マイヤーズ　スクイブ　カンパニー 乳癌細胞でのプロテインチロシンキナーゼおよび／またはプロテインチロシンキナーゼ経路と相互作用および／またはモデュレートする化合物の活性を予測するためのポリヌクレオチドの同定
WO2004020595A2 (fr) 2002-08-29 2004-03-11 Five Prime Therapeutics, Inc. Nouveaux polypeptides humains codes par des polynucleotides
AU2002951346A0 (en) 2002-09-05 2002-09-26 Garvan Institute Of Medical Research Diagnosis of ovarian cancer
JP2005537800A (ja) 2002-09-06 2005-12-15 マンカインド コーポレイション エピトープ配列
US20060134109A1 (en) 2002-09-09 2006-06-22 Nura Inc. G protein coupled receptors and uses thereof
JP2004113151A (ja) 2002-09-27 2004-04-15 Sankyo Co Ltd 癌遺伝子及びその用途
AU2003278002A1 (en) 2002-10-03 2004-04-23 Mcgill Univeristy Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics
CA2501131A1 (fr) 2002-10-04 2004-04-22 Van Andel Research Institute Sous classification moleculaire de tumeurs renales et decouverte de nouveaux marqueurs diagnostiques
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004044178A2 (fr) 2002-11-13 2004-05-27 Genentech, Inc. Procedes et compositions pour diagnostiquer une dysplasie
WO2004045553A2 (fr) 2002-11-15 2004-06-03 The Board Of Trustees Of The University Of Arkansas Gene ca125 et utilisation de celui-ci aux fins d'interventions diagnostiques et therapeutiques
CA2505601C (fr) 2002-11-15 2014-10-28 Musc Foundation For Research Development Modulateurs de complement cibles sur le recepteur 2 de complement
AU2003297300A1 (en) 2002-11-20 2004-06-15 Biogen Idec Inc. Novel gene targets and ligands that bind thereto for treatment and diagnosis of carcinomas
EP2410332A1 (fr) 2002-11-21 2012-01-25 The University Of Utah Méthode d'identification de modulateurs purinergiques du système olfactif
WO2004048938A2 (fr) 2002-11-26 2004-06-10 Protein Design Labs, Inc. Procedes de detection du sarcome des tissus mous, compositions et procedes de criblage des modulateurs du sarcome des tissus mous
WO2004053079A2 (fr) 2002-12-06 2004-06-24 Diadexus, Inc. Compositions, variants d'epissage et methodes concernant des genes et des proteines specifiques des ovaires
JP2004198419A (ja) 2002-12-13 2004-07-15 Bayer Healthcare Llc Ｔｉｍｐ１を用いた検出方法
PL212899B1 (pl) 2002-12-16 2012-12-31 Genentech Inc Humanizowane przeciwcialo, kompozycja zawierajaca to przeciwcialo, wyrób fabryczny, przeciwcialo lub jego fragment do zastosowania w sposobie indukowania apoptozy, izolowany kwas nukleinowy, wektor ekspresji, komórka gospodarza, sposób wytwarzania przeciwciala lub jego fragmentu, plynny preparat i zastosowanie przeciwciala do wytwarzania leku
CA2510315C (fr) 2002-12-20 2014-01-28 Protein Design Labs, Inc. Anticorps anti-gpr64 et utilisations
US20050249671A9 (en) 2002-12-23 2005-11-10 David Parmelee Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof
JP2007520995A (ja) 2003-01-08 2007-08-02 ブリストル−マイヤーズ　スクイブ　カンパニー 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
US20050227301A1 (en) 2003-01-10 2005-10-13 Polgen Cell cycle progression proteins
WO2004063355A2 (fr) 2003-01-10 2004-07-29 Protein Design Labs, Inc. Nouveaux procedes de diagnostic d'un cancer metastatique, compositions et procedes de depister des modulateurs du cancer metastatique
EP1583820A4 (fr) 2003-01-14 2007-07-18 Bristol Myers Squibb Co Polynucleotides et polypeptides associes a la voie nf-kb
WO2004065576A2 (fr) 2003-01-15 2004-08-05 Millennium Pharmaceuticals, Inc. Methodes et compositions de traitement de troubles urologiques a l'aide de genes 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579, 15985, 15625, 760, 18603,
EP1585767A2 (fr) 2003-01-16 2005-10-19 Genentech, Inc. Banques de phages anticorps synthetiques
EP1594893A2 (fr) 2003-02-14 2005-11-16 Sagres Discovery, Inc. Cibles therapeutiques pour le cancer
US20030224411A1 (en) 2003-03-13 2003-12-04 Stanton Lawrence W. Genes that are up- or down-regulated during differentiation of human embryonic stem cells
EP1608664B1 (fr) 2003-03-31 2009-01-28 Council of Scientific and Industrial Research Pyrrolo[2,1-c][1,4]benzodiazepines non-reticulees comme agents anticancereux potentiels et leur procede de preparation
RU2314309C2 (ru) * 2003-03-31 2008-01-10 Каунсил Оф Сайентифик Энд Индастриал Рисерч Пирроло [2.1-c][1.4] бензодиазепины, способ их получения и фармацевтическая композиция на их основе
GB0321295D0 (en) 2003-09-11 2003-10-15 Spirogen Ltd Synthesis of protected pyrrolobenzodiazepines
CA2542046A1 (fr) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Composition proteique hybride
CA2542125A1 (fr) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Procede permettant de produire une composition d'anticorps par inhibition par l'arn de la fonction de .alpha.1,6-fucosyltransferase
HUE031632T2 (en) 2003-11-05 2017-07-28 Roche Glycart Ag Antigen binding molecules with enhanced Fc receptor binding affinity and effector function
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
EP1720881B9 (fr) 2004-03-01 2013-04-17 Spirogen Sàrl Derives de 11-hydroxy-5h-pyrrolo[2,1-c][1,4] benzodiazepine-5-one en tant qu'intermediaires cles pour la preparation de pyrrolobenzodiazepines substituees c2
JP5128935B2 (ja) 2004-03-31 2013-01-23 ジェネンテック， インコーポレイテッド ヒト化抗ＴＧＦ−β抗体
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP2360186B1 (fr) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anticorps dirigés contre la sélectine P
FR2869231B1 (fr) 2004-04-27 2008-03-14 Sod Conseils Rech Applic Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
NZ580115A (en) 2004-09-23 2010-10-29 Genentech Inc Cysteine engineered antibody light chains and conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
PL1846030T3 (pl) 2005-01-21 2019-05-31 Genentech Inc Ustalone dawkowanie przeciwciał her
MX2007009889A (es) 2005-02-23 2007-09-07 Genentech Inc Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer.
EP1957531B1 (fr) 2005-11-07 2016-04-13 Genentech, Inc. Polypeptides de liaison comprenant des sequences diversifiees et des sequences consensus hypervariables vh/vl
EP1973951A2 (fr) 2005-12-02 2008-10-01 Genentech, Inc. Polypeptides de liaison avec des sequences de diversite limitees
EP1813614B1 (fr) 2006-01-25 2011-10-05 Sanofi Agents cytotoxiques comprenant de nouveaux dérivés de Tomaymycine
TW200812616A (en) 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
ES2567402T3 (es) 2006-05-30 2016-04-22 Genentech, Inc. Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos
EP1864682A1 (fr) * 2006-06-09 2007-12-12 Sanofi-Aventis Dérivés de la Leptomycine
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
US8592562B2 (en) 2008-01-07 2013-11-26 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
GB0819097D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
SG2014009138A (en) 2009-02-05 2014-03-28 Immunogen Inc Novel benzodiazepine derivatives
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
EP2536756B1 (fr) 2010-02-16 2018-04-25 MedImmune, LLC Compositions relatives a l'albumine serique humaine et leurs methodes d'utilisation
CN102167742B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗her2单克隆抗体、其制备方法及用途
AU2011239525B2 (en) 2010-04-15 2015-04-09 Medimmune Limited Pyrrolobenzodiazepines used to treat proliferative diseases
CA2793890C (fr) 2010-04-15 2017-08-15 Spirogen Developments Sarl Pyrrolobenzodiazepines et conjugues de celles-ci
CN107019804A (zh) 2010-04-15 2017-08-08 西雅图基因公司 靶向吡咯并苯并二氮杂卓结合物
JP6048972B2 (ja) 2010-04-23 2016-12-21 ジェネンテック， インコーポレイテッド ヘテロ多量体タンパク質の産生
KR101839163B1 (ko) 2010-06-08 2018-03-15 제넨테크, 인크. 시스테인 조작된 항체 및 접합체
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
CA2816426A1 (fr) * 2010-11-17 2012-06-07 Genentech, Inc. Conjugues d'anticorps alaninyl-maytansinol
RU2013140685A (ru) 2011-02-04 2015-03-10 Дженентек, Инк. ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ
SG191965A1 (en) 2011-02-15 2013-08-30 Immunogen Inc Methods of preparation of conjugates
DK2691417T3 (en) 2011-03-29 2018-11-19 Roche Glycart Ag ANTIBODY FC VARIANTS
WO2013017705A1 (fr) 2011-08-03 2013-02-07 Salvador Moreno Rufino Baltasar Système de panneau de construction avec rétroéclairage à base de diodes électroluminescentes
CN103987718A (zh) 2011-09-20 2014-08-13 斯皮罗根有限公司 作为非对称二聚体pbd化合物用于内含在靶向结合物中的吡咯并苯并二氮杂卓
KR101961976B1 (ko) 2011-10-14 2019-03-25 시애틀 지네틱스, 인크. 피롤로벤조디아제핀 및 표적 접합체
EP2750713B1 (fr) * 2011-10-14 2015-09-16 Spirogen Sàrl Pyrrolobenzodiazépines et conjugués associés
WO2013053873A1 (fr) 2011-10-14 2013-04-18 Spirogen Sàrl Pyrrolobenzodiazépines
CN103987384A (zh) 2011-10-14 2014-08-13 西雅图基因公司 吡咯并苯并二氮杂卓和靶向结合物
AR091033A1 (es) 2012-05-14 2014-12-30 Sanofi Sa Metodo para producir 11-des-o-metiltomaimicina recombinante
US9724427B2 (en) 2012-05-21 2017-08-08 Genentech, Inc. Anti-Ly6E antibodies and immunoconjugates and methods of use
WO2013177481A1 (fr) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazépines et leurs conjugués
BR112015000441A2 (pt) * 2012-07-09 2017-12-19 Genentech Inc imunoconjugados, formulação farmacêutica e método de tratamento e método para inbir a proliferação de uma célula positiva para cd22
ES2703151T3 (es) 2012-10-12 2019-03-07 Adc Therapeutics Sa Conjugados de anticuerpos de pirrolobenzodiazepinas
AU2013328673B2 (en) 2012-10-12 2017-07-13 Medimmune Limited Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
KR20150083856A (ko) 2012-10-12 2015-07-20 에이디씨 테라퓨틱스 에스에이알엘 피롤로벤조디아제핀-항-her2 항체 컨주게이트
WO2014057118A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sarl Conjugués anticorps anti-cd22 - pyrrolobenzodiazépine
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
EP2906253B9 (fr) 2012-10-12 2019-04-10 ADC Therapeutics SA Conjugués anticorps anti-psma - pyrrolobenzodiazépine
KR20200003278A (ko) 2012-10-12 2020-01-08 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
PT2906296T (pt) 2012-10-12 2018-06-01 Medimmune Ltd Conjugados de pirrolobenzodiazepina-anticorpo
CN105102004B (zh) 2012-10-12 2019-01-25 Adc疗法责任有限公司 吡咯并苯并二氮杂卓-抗cd22抗体结合物
EP2906297B1 (fr) 2012-10-12 2017-12-06 ADC Therapeutics SA Conjugués anticorps - pyrrolobenzodiazépine
CN105246894A (zh) 2012-12-21 2016-01-13 斯皮罗根有限公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
BR112015014669B1 (pt) * 2012-12-21 2023-09-26 Medimmune Limited Compostos pirrolobenzodiazepinas, conjugados compreendendo os mesmos e uso destes para tratar uma doença proliferativa
JP6462591B2 (ja) 2013-02-22 2019-01-30 アッヴィ・ステムセントルクス・エル・エル・シー 新規抗体コンジュゲートおよびその使用
WO2015023355A1 (fr) * 2013-08-12 2015-02-19 Genentech, Inc. Conjugués anticorps-médicament dimérique 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement
EP3082874A2 (fr) * 2013-12-16 2016-10-26 Genentech, Inc. Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci
KR102337414B1 (ko) 2013-12-16 2021-12-10 제넨테크, 인크. 펩타이드 모방체 화합물 및 이의 항체-약물 컨쥬게이트
MY186334A (en) 2014-09-12 2021-07-12 Genentech Inc Anti-her2 antibodies and immunoconjugates
KR20170052600A (ko) 2014-09-12 2017-05-12 제넨테크, 인크. 시스테인 가공된 항체 및 콘주게이트
CA2957148A1 (fr) 2014-09-17 2016-03-24 Genentech, Inc. Immunoconjugues comprenant des anticorps anti-her2 et des pyrrolobenzodiazepines
MX2017003523A (es) 2014-09-17 2017-11-08 Genentech Inc Pirrolobenzodiazepinas y conjugados de anticuerpo-disulfuro de las mismas.
GB201513607D0 (en) * 2015-07-31 2015-09-16 Feingold Jay M Pyrrolobenzodiazepine-antibody conjugates
WO2015155753A2 (fr) 2015-08-10 2015-10-15 Suzhou M-Conj Biotech Co., Ltd Nouvelles séquences de liaison et leurs utilisation pour la conjugaison spécifique de médicaments à une molécule biologique
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation

Also Published As

Publication number Publication date
CN108391422B (zh) 2021-10-22
CO2018004152A2 (es) 2018-07-19
US10058613B2 (en) 2018-08-28
ZA201801957B (en) 2020-07-29
CR20180243A (es) 2018-07-31
MX2018003628A (es) 2018-08-01
KR20180054849A (ko) 2018-05-24
RU2736725C1 (ru) 2020-11-19
WO2017059289A1 (fr) 2017-04-06
UA123104C2 (uk) 2021-02-17
JP2019218405A (ja) 2019-12-26
BR112018006016A2 (pt) 2019-01-29
CA2996902C (fr) 2020-06-02
EP3355935A1 (fr) 2018-08-08
SG10201912680RA (en) 2020-03-30
AU2016331931C1 (en) 2020-01-16
AU2016331931A1 (en) 2018-04-12
JP6663984B2 (ja) 2020-03-13
CA2996902A1 (fr) 2017-04-06
HK1259127A1 (zh) 2019-11-22
EP3355935B1 (fr) 2020-10-21
US20170095570A1 (en) 2017-04-06
AU2016331931B2 (en) 2019-09-26
CN108391422A (zh) 2018-08-10
US10639373B2 (en) 2020-05-05
JP2021167356A (ja) 2021-10-21
US20180185486A1 (en) 2018-07-05
NZ741261A (en) 2019-11-29
PH12018500693A1 (en) 2018-10-01
TW201718027A (zh) 2017-06-01
US20180326062A1 (en) 2018-11-15
JP2018530545A (ja) 2018-10-18
PE20181067A1 (es) 2018-07-04
IL258046A (en) 2018-05-31
US10632196B2 (en) 2020-04-28
CL2018000813A1 (es) 2019-02-22
AR106235A1 (es) 2017-12-27
KR102111338B1 (ko) 2020-05-15

Similar Documents

Publication Publication Date Title
PH12018500693A1 (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
CY1121949T1 (el) Φαρμακοτεχνικες μορφες συζευγματος anti-egfr αντισωματος-φαρμακου
CY1123783T1 (el) Antiσωμαta enanti-b7-h3 και συζευγματα αντισωματος φαρμακου
MX2021010550A (es) Conjugados de anticuerpo-farmaco hidrofilicos.
MX2019005879A (es) Enlazadores que contienen peptido para conjugados anticuerpo-farmaco.
CY1122472T1 (el) Συζευγμα-αντισωματος-φαρμακου και η χρηση αυτου για την αγωγη του καρκινου
MA51447A (fr) Conjugué anticorps monoclonal-médicament dirigé contre bcma
MA37840A3 (fr) Immunoconjugués comprenant des anticorps anti-cd79b
MA47468A (fr) Anticorps anti-ilt3 et conjugués anticorps-médicament
PE20150892A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
PH12016501995A1 (en) Tubulysin derivatives
CY1122449T1 (el) Σχηματα δοσολογιας ανοσοσυζευγματος enanti-folr1
PH12016500246A1 (en) 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
MX2021008334A (es) Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-farmaco.
EP3630189A4 (fr) Lieurs pour conjugués anticorps-médicament
BR112019023246A8 (pt) melhorias farmacocinéticas de quelatos bifuncionais e usos dos mesmos
CY1121783T1 (el) Συζευγμα αντισωματος-igf-1r-φαρμακου και η χρηση αυτου για την αγωγη του καρκινου
MX2016007578A (es) Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento.
MA47815A (fr) Dérivés de maytansinoïdes comprenant des lieurs peptidiques auto-immolables et conjugués correspondants
CL2018000131A1 (es) Inmunoconjugados de il22
MA55818A (fr) Anticorps et immunoconjugués de fr-alpha biparatopique
IL287938A (en) Drug antibody conjugates
MA52626A (fr) Anticorps anti-cd63, conjugués et leurs utilisations
MA49273A (fr) Anticorps anti-tmeff1 et conjugués anticorps-médicament
CY1124183T1 (el) Συζευγματα αντισωματος εναντι-sez6 φαρμακου και μεθοδοi χρησης